HORIZON: A Phase II, Open-Label, Outcomes-Assessor Masked, Multicentre, Randomised, Controlled Study To Evaluate The Safety And Efficacy Of TwoDoses Of Gt005 Administered As A Single Subretinal Injection In Subjects With Geographic Atrophy Secondary